Barron’s 2020 Healthcare Roundtable say that efforts to understand the coronavirus and find a preventive vaccine have kick-started innovation all across the healthcare spectrum, from biotechnology and drug development to diagnostics and patient care.

Recent advances in technology, powered by computational biology and artificial intelligence, are driving the creation of new healthcare companies and reshaping industry leaders—and promise rich rewards for investors in both.

The post-COVID world could see a panoply of brand-new tools to solve age-old problems like cancer, kidney disease, and genetic disorders, allowing scientists to target disease pathways that weren’t recognized or understood even a few years ago, Barron's said.

The 2020 roundtable offered 10 stocks to buy now for future rewards:

1. AbbVie (ABBV)
2. FibroGen (FGEN)
3. Burning Rock Biotech (BNR)
4. Allogene Therapeutics (ALLO)
5. Relay Therapeutics (RLAY)
6. Revolution Medicines (RVMD)
7. Blueprint Medicines (BPMC)
8. Pliant Therapeutics (PLRX)
9. Humana (HUM)
10. Oak Street Health (OSH)

Meanwhile, mergers and acquisitions came back with a bang in the third quarter as executives rushed to revisit deals left on hold at the height of the coronavirus pandemic and boardrooms regained confidence after a roller-coaster year, Reuters reported.

A deal frenzy in September led to a record third quarter with more than $1 trillion worth of transactions around the world, mostly focused on coronavirus-resilient sectors such as technology and healthcare, according to Refinitiv data.

• Healthcare Stocks Show Their Defensive Allure in Ailing Market
• 'AI Healthcare' Stocks Will Mint the World's First Trillionaire